Specifically, no direct evidence exists regarding the in vivo origin of any cardiovascular side effects or whether a cardioneutral anti-obesity effect could result if AMPH is excluded from the brain. The gene discussed is AMPH; the disease is obesity due to melanocortin 4 receptor deficiency.